Meeting
2023 ASCO Annual Meeting
Management of patients with ALK-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial.
Authors
Todd Michael Bauer
Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN
Todd Michael Bauer , Enriqueta Felip , Tony S. K. Mok , Yi-Long Wu , Geoffrey Liu , Yasushi Goto , Dong-Wan Kim , Jolanda Paolini , Anna Polli , Benjamin J. Solomon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03052608
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9063)
DOI
10.1200/JCO.2023.41.16_suppl.9063
Abstract #
9063
Poster Bd #
51
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK+ advanced non–small cell lung cancer (NSCLC).
First Author: Benjamin J. Solomon
Poster
2022 ASCO Annual Meeting
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.
First Author: Alessandra Bearz
Poster
2023 ASCO Annual Meeting
First-in-human, multicenter phase Ⅰ study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer.
First Author: Hongyun Zhao
Poster
2020 ASCO Virtual Scientific Program
Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort.
First Author: Simon Baldacci